|Injection into pleural space or abdomen|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||477.64 g·mol−1|
|3D model (JSmol)|
Batimastat (mnemonic: batty-mustard) (INN/USAN, codenamed BB-94) is a drug that was invented by Colin Campion et al. of British Biotech (now Vernalis). It is an antimetastatic drug that belongs to the family of drugs called angiogenesis inhibitors. It acts as a matrix metalloproteinase inhibitor (MMPI) by mimicking natural MMPI peptides. Dan Lednicer wrote about this compound in book #6 of his organic drug synthesis series.
Batimastat was the first MMPI that went into clinical trials. First results of a Phase I trial appeared in 1994. The drug reached Phase III but was never marketed; mainly because it couldn't be administered orally (as opposed to the newer and chemically similar MMPI marimastat), and injection into the peritoneum caused peritonitis.
It is well-known that other methods of administration include transdermal (skin lotion) as well as rectal suppositories.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|